Assignee
ZYMEWORKS BC INC
CA·17 granted patents·28 pending applications·0 citations·filing 2018–2025
Top patents by PatentIndex Score
45 records- 0190US2025122305A1Bispecific antigen binding constructs targeting her2ZYMEWORKS BC INC·Filed 2024·Application pending·0 cites
- 0285US2025197527A1STABLE HETERODIMERIC ANTIBODY DESIGN WITH MUTATIONS IN THE Fc DOMAINZYMEWORKS BC INC·Filed 2024·Application pending·0 cites
- 0384US2024343802A1Bispecific Asymmetric Heterodimers Comprising Anti-CD3 ConstructsZYMEWORKS BC INC·Filed 2024·Application pending·0 cites
- 0482US12303544B2Cytotoxic and anti-mitotic compounds, and methods of using the sameZYMEWORKS BC INC·Filed 2023·Granted May 20, 2025·0 cites·24 claims
- 0581US12215166B2Bispecific antigen binding constructs targeting HER2ZYMEWORKS BC INC·Filed 2022·Granted Feb 4, 2025·0 cites·23 claims
- 0681US2025084184A1Methods of using bispecific antigen-binding constructs targeting her2ZYMEWORKS BC INC·Filed 2024·Application pending·0 cites
- 0780US12152083B2Cytotoxic and anti-mitotic compounds, and methods of using the sameZYMEWORKS BC INC·Filed 2023·Granted Nov 26, 2024·0 cites·27 claims
- 0876US11965036B2Bispecific antigen-binding constructs targeting HER2ZYMEWORKS BC INC·Filed 2021·Granted Apr 23, 2024·0 cites·19 claims
- 0972US12304945B2Engineered immunoglobulin heavy chain-light chain pairs and uses thereofZYMEWORKS BC INC·Filed 2022·Granted May 20, 2025·0 cites·20 claims
- 1072US11617777B2Cytotoxic and anti-mitotic compounds, and methods of using the sameZYMEWORKS BC INC·Filed 2019·Granted Apr 4, 2023·0 cites·23 claims
- 1171US12286489B2Modified antigen binding polypeptide constructs and uses thereofZYMEWORKS BC INC·Filed 2022·Granted Apr 29, 2025·0 cites·40 claims
- 1271US2025009788A1Methods of using a bispecific antigen-binding construct targeting her2 in combination with cdk4/6 inhibitors for the treatment of breast cancerZYMEWORKS BC INC·Filed 2024·Application pending·0 cites
- 1371US2024327815A1Multivalent polypeptide constructs capable of binding viral spike proteins and methods of using the sameZYMEWORKS BC INC·Filed 2024·Application pending·0 cites
- 1470US2023265173A1Sulfonamide-containing linkage systems for drug conjugatesZYMEWORKS BC INC·Filed 2022·Application pending·0 cites
- 1569US12227591B2Antigen-binding constructs targeting HER2ZYMEWORKS BC INC·Filed 2021·Granted Feb 18, 2025·0 cites·19 claims
- 1669US12060436B2Engineered immunoglobulin heavy chain-light chain pairs and uses thereofZYMEWORKS BC INC·Filed 2021·Granted Aug 13, 2024·0 cites·14 claims
- 1768US2026022193A1Methods of treatment using a bispecific antigen-binding construct targeting her2ZYMEWORKS BC INC·Filed 2025·Application pending·0 cites
- 1867US2024228567A1Modified interleukin p40 subunit proteins and methods of use thereofZYMEWORKS BC INC·Filed 2024·Application pending·0 cites
- 1967US2025215115A1Modified antigen bindingpolypeptide constructs and uses thereofZYMEWORKS BC INC·Filed 2025·Application pending·0 cites
- 2066US12433952B2Antibody-drug conjugates targeting folate receptor alpha and methods of useZYMEWORKS BC INC·Filed 2024·Granted Oct 7, 2025·0 cites·30 claims
- 2166US12157775B2Methods of using bispecific antigen-binding constructs targeting HER2ZYMEWORKS BC INC·Filed 2020·Granted Dec 3, 2024·0 cites·23 claims
- 2265US12357701B2Anti-HER2 biparatopic antibody-drug conjugates and methods of useZYMEWORKS BC INC·Filed 2021·Granted Jul 15, 2025·0 cites·33 claims
- 2364US12435157B2Methods of using a bispecific antigen-binding construct targeting HER2 for the treatment of biliary tract cancersZYMEWORKS BC INC·Filed 2021·Granted Oct 7, 2025·0 cites·26 claims
- 2462US12540198B2Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereofZYMEWORKS BC INC·Filed 2021·Granted Feb 3, 2026·0 cites·26 claims
- 2562US11591405B2Cytotoxic and anti-mitotic compounds, and methods of using the sameZYMEWORKS BC INC·Filed 2019·Granted Feb 28, 2023·0 cites·18 claims
- 2660US2025339552A1Antibody-drug conjugates targeting folate receptor alpha and methods of useZYMEWORKS BC INC·Filed 2025·Application pending·0 cites
- 2759US2025014673A1Systems and methods for polymer side-chain conformation predictionZYMEWORKS BC INC·Filed 2022·Application pending·0 cites
- 2858US2025014683A1Systems and methods for polymer sequence predictionZYMEWORKS BC INC·Filed 2022·Application pending·0 cites
- 2958US2025019440A1Immunomodulatory trispecific t cell engager fusion proteinsZYMEWORKS BC INC·Filed 2024·Application pending·0 cites
- 3058US2024376154A1Bis-intercalating peptides, conjugates and methods of useZYMEWORKS BC INC·Filed 2024·Application pending·0 cites
- 3158US2024294667A9Heterodimeric iga fc constructs and methods of use thereofZYMEWORKS BC INC·Filed 2021·Application pending·0 cites
- 3256US2024239915A1Fc variant with high thermal stability and attenuated effector functionZYMEWORKS BC INC·Filed 2024·Application pending·0 cites
- 3355US2024409604A9Stabilized tcr constructs and methods of useZYMEWORKS BC INC·Filed 2021·Application pending·0 cites
- 3454US2025136714A1Methods of treating cancer with anti-her2 biparatopic antibodiesZYMEWORKS BC INC·Filed 2022·Application pending·0 cites
- 3553US12304954B2Multivalent and bispecific antibody constructs and methods of use thereofZYMEWORKS BC INC·Filed 2024·Granted May 20, 2025·0 cites·30 claims
- 3651US2024294646A1HETERODIMERIC Fc VARIANTS SELECTIVE FOR Fc GAMMA RIIBZYMEWORKS BC INC·Filed 2021·Application pending·0 cites
- 3749US2025222128A1Antibody drug-conjugates targeting c-met and methods of use thereofZYMEWORKS BC INC·Filed 2025·Application pending·0 cites
- 3847US2025179088A9Imidazothienopyridine compounds and methods of useZYMEWORKS BC INC·Filed 2021·Application pending·0 cites
- 3946US2023303715A1IMMUNOGLOBULIN Fc REGION VARIANTS COMPRISING STABILITY-ENHANCING MUTATIONSZYMEWORKS BC INC·Filed 2021·Application pending·0 cites
- 4043US2025235548A1Antibody-drug conjugates targeting napi2b and methods of useZYMEWORKS BC INC·Filed 2025·Application pending·0 cites
- 4143US2025295799A1Antibody-drug conjugates targeting glypican-3 and methods of useZYMEWORKS BC INC·Filed 2025·Application pending·0 cites
- 4242US11965019B2Stabilized chimeric FabsZYMEWORKS BC INC·Filed 2018·Granted Apr 23, 2024·0 cites·25 claims
- 4342US2025277030A1Anti-napi2b antibodies and methods of useZYMEWORKS BC INC·Filed 2025·Application pending·0 cites
- 4442US2025170266A1Immunomodulator purine-derived compounds, conjugates thereof, and methods of use thereofZYMEWORKS BC INC·Filed 2025·Application pending·0 cites
- 4539US2026028403A1Trivalent and trispecific antibody constructs and methods of use thereofZYMEWORKS BC INC·Filed 2025·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →